Joseph K. Belanoff, M.D., co-founder and CEO of Corcept Therapeutics since 1999, combines a strong medical background with deep experience in the pharma industry. He has an impressive educational background; he earned his B.A. from Amherst College and his M.D....

Joseph K. Belanoff, M.D., co-founder and CEO of Corcept Therapeutics since 1999, combines a strong medical background with deep experience in the pharma industry. He has an impressive educational background; he earned his B.A. from Amherst College and his M.D. from Columbia University’s prestigious College of Physicians & Surgeons. Notably, Dr. Belanoff has been a clinical faculty member at Stanford University for decades, where he has contributed to the field of psychiatry. His leadership at Corcept has been pivotal during significant milestones, including the approval of their drug, Korlym™, for treating Cushing's syndrome, which has made a real impact on patients' lives. In 2023, his total compensation was $2,652,500, reflecting his role in driving the company's performance and aligning with healthcare goals. As a CEO, he emphasizes attracting talented personnel to ensure the company meets its clinical and commercial objectives. His keen focus on scientific and regulatory achievements showcases his strategic approach to building Corcept into a leading therapeutic company.